Xencor Q2 Results: Pipeline Progress, XmAb819 ESMO Spotlight, and XmAb541 Combo Pivot
XNCR has more than doubled off its 52-week low of $6.92.
Summary
Xencor reported Q2 2026 financials alongside a pipeline update. The key clinical news: Phase 1 XmAb819 (ENPP3 x CD3) data in advanced ccRCC was accepted for an oral presentation at ESMO in October, with a registration-enabling study planned for 2027. The company is prioritizing the XmAb541/XmAb808 combination over monotherapy after seeing moderate activity and hearing-related toxicity at higher doses; monotherapy showed 14% ORR in ovarian and 28% in germ cell tumors. XmAb412, a XenLock bispecific, entered Phase 1. The update follows the recent $105M Alexion royalty resolution, which removed a financial overhang. No specific Q2 revenue or EPS figures were disclosed in the release, limiting immediate financial impact, but the pipeline catalysts are material for a $1.5B market cap biotech.
At the time of this announcement, XNCR was trading at $19.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $6.92 to $21.76. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.